Filing Details
- Accession Number:
- 0000899243-23-002075
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-18 17:58:22
- Reporting Period:
- 2023-01-13
- Accepted Time:
- 2023-01-18 17:58:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1590750 | Viridian Therapeutics Inc. | VRDN | Services-Medical Laboratories (8071) | 471187261 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1841628 | Barrett Katz | C/O Viridian Therapeutics, Inc. 221 Crescent Street, Suite 401 Waltham MA 02453 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-01-13 | 4,147 | $23.03 | 4,147 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-13 | 4,147 | $37.01 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2023-01-17 | 24,853 | $23.03 | 24,853 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-01-17 | 24,853 | $37.21 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-01-13 | 4,147 | $0.00 | 4,147 | $23.03 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-01-17 | 24,853 | $0.00 | 24,853 | $23.03 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 291,853 | 2031-01-17 | No | 4 | M | Direct | |
| 267,000 | 2031-01-17 | No | 4 | M | Direct |
Footnotes
- This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.58. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
Billionaire Hedge Funds
